Welcome to our dedicated page for Alkermes news (Ticker: ALKS), a resource for investors and traders seeking the latest updates and insights on Alkermes stock.
Alkermes plc develops and commercializes neuroscience medicines, with proprietary commercial products used in alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Company news commonly covers quarterly financial results, full-year expectations, commercial execution and presentations at healthcare and CNS investor conferences.
Clinical and medical updates focus on the company’s sleep-wake and psychiatric portfolio, including LYBALVI in schizophrenia and bipolar I disorder and alixorexton, an investigational oral selective orexin 2 receptor agonist in development for narcolepsy and idiopathic hypersomnia. Other updates include peer-reviewed data publications, research award programs and corporate developments tied to Alkermes’ biopharmaceutical operations.
Alkermes plc (Nasdaq: ALKS) will host a conference call on July 29, 2020, at 8:00 a.m. ET to discuss its second quarter 2020 financial results. The call will provide insights into the company's performance and updates on business developments. Investors can access the webcast on Alkermes' website. A replay will be available from 11:00 a.m. ET on the same day through August 5, 2020. Alkermes, based in Dublin, specializes in neuroscience and oncology, focusing on innovative treatments for addiction, schizophrenia, and cancer.
Alkermes plc (Nasdaq: ALKS) announced the opening of applications for its annual Alkermes Pathways Research Awards program starting July 1, 2020. The program, now in its third year, supports early-career researchers focused on neuroscience, particularly in substance use disorders, schizophrenia, and bipolar disorder. Grants of up to $100,000 will be awarded to qualifying M.D.s, Ph.D.s, or post-doctoral fellows. The application period will close on October 30, 2020.